Inogen delivered Q2 2026 results that surpassed revenue expectations but posted a net loss, reflecting persistent pressures from reimbursement dynamics and competitive intensity in the respiratory medical device space. The company’s core business remains focused on portable oxygen concentrators (POCs) sold and rented primarily through a direct-to-consumer model leveraging Medicare reimbursement, supplemented by stationary concentrators, airway clearance devices, and CPAP masks. Inogen’s moat is supported by proprietary pulse-dose technology and regulatory barriers inherent in rental programs but challenged by supply chain concentration and evolving payor policies. Sustained growth will depend on expanding device usage, maintaining rental customer counts, navigating reimbursement changes, and broadening geographic reach through collaborations like with Yuwell.